Data / Research funding / California / Max Biopharma, Inc.
Max Biopharma, Inc.: 4 NIH awards ($4.1M), fiscal years 2021 to 2026
Max Biopharma, Inc. in Los Angeles, CA is funded under 4 NIH awards ($4.1M) in the NIH and NSF award files, read 2026-11-03. NIH fiscal years 2021 to 2025; NSF fiscal years 2022 to 2026.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- UEI
- NZ8XY5DKRAD3
- State
- California
Awards
4 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|
| Evaluation of anti-fibrotic and anti-inflammatory semi-synthetic oxysterol, Oxy210, as a therapeutic drug candidate for non-alcoholic steatohepatitis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2024 | $1,786,691 | May 1, 2023 | April 30, 2026 | PARHAMI, FARHAD | reporter.nih.gov |
| Therapeutic Development of Osteogenic Oxysterol, Oxy133, for Spine Fusion | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2022 | $1,707,540 | September 1, 2021 | August 31, 2024 | PARHAMI, FARHAD | reporter.nih.gov |
| Effect of a semi-synthetic oxysterol drug candidate, Oxy210, on atherosclerosis in a mouse model of NASH | NIH | National Heart, Lung, and Blood Institute | 2022 | $320,724 | May 23, 2022 | April 30, 2024 | PARHAMI, FARHAD | reporter.nih.gov |
| An oxysterol drug candidate, Oxy210, for inhibition of pulmonary fibrosis through targeting hedgehog and TGFβ signaling | NIH | National Heart, Lung, and Blood Institute | 2022 | $318,089 | August 10, 2022 | July 31, 2024 | PARHAMI, FARHAD | reporter.nih.gov |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|
| 2024 | 1 | $889,701 | 0 | $0 |
| 2023 | 1 | $896,990 | 0 | $0 |
| 2022 | 3 | $1,491,200 | 0 | $0 |
| 2021 | 1 | $855,153 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|
| Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R61 Clinical Trial Required) | PAR-24-279 | NIH | 93.846 | November 2, 2026 | Not listed | Same assistance listing 93.846 as 1 award here |
| Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed) | PAR-24-280 | NIH | 93.846 | November 2, 2026 | Not listed | Same assistance listing 93.846 as 1 award here |
| Limited Competition for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Clinical Centers (U01 Clinical Trial Required) | RFA-DK-27-125 | NIH | 93.847 | November 6, 2026 | Not listed | Same assistance listing 93.847 as 1 award here |
| Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed) | RFA-DK-27-112 | NIH | 93.847 | November 9, 2026 | Not listed | Same assistance listing 93.847 as 1 award here |
| Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required) | RFA-DK-27-139 | NIH | 93.847 | November 9, 2026 | Not listed | Same assistance listing 93.847 as 1 award here |
| Single Source for the Continuation of the Physiology of the Weight Reduced State (POWERS) Study (U01- Clinical Trials Required) | RFA-DK-27-122 | NIH | 93.847 | November 17, 2026 | Not listed | Same assistance listing 93.847 as 1 award here |
| HEAL Initiative: Pain Research Enhancement Program (PREP) (R15 Clinical Trial Optional) | RFA-AT-25-003 | NIH | 93.846 | November 23, 2026 | $375,000 | Same assistance listing 93.846 as 1 award here |
| Restoring Joint Health and Function to Reduce Pain (RE-JOIN) 2.0 | RFA-AR-26-006 | NIH | 93.846 | December 1, 2026 | Not listed | Same assistance listing 93.846 as 1 award here |
| Emerging Global Leader Award (K43 Independent Clinical Trial Required) | PAR-24-295 | NIH | 93.837 | December 3, 2026 | Not listed | Same assistance listing 93.837 as 1 award here |
| Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed) | PAR-24-296 | NIH | 93.837 | December 3, 2026 | Not listed | Same assistance listing 93.837 as 1 award here |
| NIH Research Software Engineer (RSE) Award (R50 Clinical Trials Not Allowed) | RFA-OD-24-011 | NIH | 93.846 | December 4, 2026 | Not listed | Same assistance listing 93.846 as 1 award here |
| Small Business Transition Grant for New Entrepreneurs (Parent R43/R44 Clinical Trial Optional) | PAR-27-039 | NIH | 93.846 | January 5, 2027 | Not listed | Same assistance listing 93.846 as 1 award here |
| Small Business Transition Grant for New Entrepreneurs (Parent R41/R42 Clinical Trial Optional) | PAR-27-040 | NIH | 93.846 | January 5, 2027 | Not listed | Same assistance listing 93.846 as 1 award here |
| Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required) | PAR-24-214 | NIH | 93.837 | January 7, 2027 | $375,000 | Same assistance listing 93.837 as 1 award here |
| Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) | PAR-25-379 | NIH | 93.846 | January 7, 2027 | Not listed | Same assistance listing 93.846 as 1 award here |
| HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed) | RFA-NS-25-023 | NIH | 93.846 | January 15, 2027 | $350,000 | Same assistance listing 93.846 as 1 award here |
| Biomedical Research Environment and Sponsored Programs Administration Development (BRE-SPAD) Program (UC2- Clinical Trial Not Allowed) | PAR-24-268 | NIH | 93.846 | January 27, 2027 | $500,000 | Same assistance listing 93.846 as 1 award here |
| Diabetes Research Centers (P30 Clinical Trial Optional) | RFA-DK-26-310 | NIH | 93.847 | January 27, 2027 | $1 million | Same assistance listing 93.847 as 1 award here |
| NIDDK Multi-Purpose Resource-Related, Multi-Component Research Services Centers Cooperative Agreement (U2C - Clinical Trial Optional) | RFA-DK-28-114 | NIH | 93.847 | January 28, 2027 | Not listed | Same assistance listing 93.847 as 1 award here |
| KUH P30 Resource Core Center (P30 Clinical Trial Not Allowed) | RFA-DK-28-312 | NIH | 93.847 | January 30, 2027 | Not listed | Same assistance listing 93.847 as 1 award here |
Topics of its NIH awards
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.